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The aim here was to conduct a review of the literature on pharmacological thera-
pies for modifying the neurological status of patients with spinal cord injuries. The
PubMed database was searched for articles with the terms “spinal cord injury AND
methylprednisolone/GM1/apoptosis inhibitor/calpain inhibitor/naloxone/tempol/tirilazad”,
in  Portuguese or in English, published over the last ﬁve years. Older studies were included
because of their historical importance. The pharmacological groups were divided according
to  their capacity to interfere with the physiopathological mechanisms of secondary injuries.
Use of methylprednisolone needs to be carefully weighed up: other anti-inﬂammatory
agents have shown beneﬁts in humans or in animals. GM1 does not seem to have greater
efﬁcacy than methylprednisolone, but longer-term studies are needed. Many inhibitors of
apoptosis have shown beneﬁts in in vitro studies or in animals. Naloxone has not shown
beneﬁts. Tempol inhibits the main consequences of oxidation at the level of the spinal cord
and  other antioxidant drugs seem to have an effect superior to that of methylprednisolone.
There is an urgent need to ﬁnd new treatments that improve the neurological status of
patients with spinal cord injuries. The beneﬁts from treatment with methylprednisolone
have been questioned, with concerns regarding its safety. Other drugs have been studied,
and  some of these may provide promising alternatives. Additional studies are needed in
order  to reach conclusions regarding the beneﬁts of these agents in clinical practice.
©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved.
O  papel  da  farmacoterapia  na  modiﬁcac¸ão  do  estado  neurológico  de
traumatizados  vértebro-medulares
r  e  s  u  m  oalavras-chave:
raumatismos da medula espinal
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O objetivo deste trabalho foi fazer uma revisão da literatura sobre a terapia farmacológ-
ica  para a modiﬁcac¸ão do estado neurológico de traumatizados vértebro-medulares. Foi
feita uma na base de dados Pubmed por artigos com os termos “spinal cord injury AND
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Naloxona
methylprednisolone/GM1/apoptosis inhibitor/calpain inhibitor/naloxone/tempol/tirilazad”,
em português ou em inglês, publicados nos últimos cinco anos. Trabalhos mais antigos
foram incluídos pela sua importância histórica. Os grupos farmacológicos foram divididos
em  func¸ão da sua capacidade para interferir nos mecanismos ﬁsiopatológicos da lesão
secundária. O uso de metilprednisolona deve ser cuidadosamente ponderado. Outros
anti-inﬂamatórios mostraram benefícios em humanos ou em animais. O GM1 não aparenta
ter  maior eﬁcácia do que a MP, mas estudos em mais longo prazo são necessários. Muitos
inibidores da apoptose têm mostrado benefício em estudos in vitro ou em animais. A nalox-
ona não deu mostras de benefício. O tempol inibe as principais consequências da oxidac¸ão
no  nível da medula e outros fármacos antioxidantes aparentam ter um efeito superior
ao  da metilprednisolona. É urgente encontrar novos tratamentos que melhorem o estado
neurológico dos traumatizados vértebro-medulares. Os benefícios do tratamento com
metilprednisolona têm sido questionados, há preocupac¸ões em relac¸ão à sua seguranc¸a.
Outros fármacos têm sido estudados, podem alguns deles ser opc¸ões promissoras. Estudos
adicionais são necessários para tirar conclusões sobre o benefício desses agentes na prática
clínica.
©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Todos os direitos reservados.
protein-1, neutrophil activating peptide-2, intercellular adhe-
sion molecule-1 (ICAM-1), soluble Fas, tissue inhibitors ofIntroduction
Spinal and spinal cord injuries are among the most dev-
astating traumatic situations and are responsible for high
morbidity and mortality rates. The consequences of these
injuries include reduction of motor and sensory capacity and
perturbations of intestinal, urinary and sexual functioning.1
The impact of these problems becomes greater through
absence of satisfactory therapy for modifying these patients’
neurological status.1
The pathogenesis of spinal cord injuries can be divided
into two phases. The primary injury occurs immediately, and
is characterized by compression, bruising or, rarely, com-
plete breakage of the spinal cord. The secondary lesions
arise over the course of several days and involve a variety
of processes, such as inﬂammation, edema, ischemia, hem-
orrhage, electrolytic imbalances, release of arachidonic acid,
excitotoxicity due to glutamate, apoptosis and lipid peroxi-
dation. These phenomena lead to expansion of the primary
lesion and cavitation of the spinal cord.1,2 Pharmacologi-
cal therapies for spinal and spinal cord injuries have the
aim of inhibiting these processes or stimulating spinal cord
regeneration.
Methylprednisolone (MP), which is frequently used in treat-
ing acute spinal cord injuries, showed evidence of beneﬁts
in the National Acute Spinal Cord Injury Survey (NASCIS) II
and NASCIS III studies.3,4 However, these ﬁndings have not
been reproduced in other studies and use of MP is becoming
increasingly controversial, because of the risk of poten-
tially serious complications, in comparison with the modest
beneﬁts.1 This has led to efforts toward developing new drugs
that might improve neurological functioning in cases of these
diseases.1
The objective of this study was to conduct a review of the
literature on pharmacological therapy for spinal and spinal
cord injuries.Materials  and  methods
A search for articles was conducted in the PubMed
database, using the terms “spinal cord injury AND methylp-
rednisolone/GM1/apoptosis inhibitor/calpain inhibitor/nalo-
xone/tempol/tirilazad”, in Portuguese or in English, published
over the last ﬁve years. Some older studies were also included
because of their historical importance.
The pharmacological groups were divided according to
their capacity for interfering in the physiopathological mech-
anisms of secondary lesions.
Drugs  that  inhibit  inﬂammation
Subsequent to spinal and spinal cord injury, inﬂammation and
hydrolysis occur in the spinal cord, which results in destruc-
tion of neurons and microvessels.4 The main function of these
drugs is to inhibit or modify the local inﬂammatory response.
Methylprednisolone
MP is the best known and most studied anti-inﬂammatory
drug for attempting to block this process, and thus forms the
paradigm.
The NASCIS studies proposed to administer MP at high
doses (loading dose of 30 mg/kg of weight and maintenance
dose of 5.4 mg/kg/h), for 24 h if the treatment was started not
more than 3 h after the injury, or for 48 h if it was started
between 3 and 8 h after the injury.3,4
In victims of complete cervical rupture, increased lev-
els of interleukin (IL) 6, IL-8, macrophage chemoattractantmetalloproteinase-1 and matrix metalloproteinases (MMP)  2
and 9 have been observed.5 Treatment with MP after spinal
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ord injury has been found to result in signiﬁcant reduc-
ion in the activity of caspases 3, 6, 8 and 9 for a period
f up to seven days after the occurrence of the injury.6
P  induces interaction of the glucocorticoid receptor with
IF-1,  which results in transactivation of erythropoietin in
ligodendrocytes, but not in cortical neurons, which may
xplain its efﬁcacy in lesions of the white matter and inef-
cacy in lesions of the gray matter.7 MP  inhibits the death
f oligodendrocytes induced by -amino-3-hydroxy-5-methyl-
-isoxazolepropionic acid (AMPA) in a manner dependent on
he signal transducer and activation of transcription (STAT) 5
ene.8 On the other hand, the neural growth factor increases
n patients treated with MP.5
However, other experimental studies have found negative
ffects from MP. In vitro, signiﬁcant inhibition of the prolifer-
tion of neuron progenitor cells that were incubated with MP
or at least ﬁve days was observed, along with alterations to
he expression of 143 genes, among which some are involved
n regulating cell proliferation and apoptosis.9
MP  was found to chronically reduce proliferation and acti-
ation of microglia and macrophages and the number of
ligodendrocyte progenitor cells, and to inhibit proliferation
f neuron progenitor cells of the hippocampus and medulla.10
In animals treated with MP, a signiﬁcant reduction in cil-
ary neurotrophic factor (a neuroprotective molecule) was
bserved 12 and 24 h after spinal cord injury. At six, 48 and
2 h, no statistically signiﬁcant differences were found.11
In therapeutic terms, rats treated with MP have shown
igniﬁcant improvements in neurological function, with
educed latency and threshold and increased evoked motor
otential.12 In another animal study, no signiﬁcant improve-
ent in neurological recovery or in the quantity of injured
issue was observed through treatment with MP.13 A review
valuated the validity of animal trials for studying treatments
or spinal cord injuries. Among the studies included, 34%
ound that MP  had beneﬁcial effects, 58% did not ﬁnd any such
ffects and 8% had mixed results, and there were inconsistent
esults between species and within each species. This review
oncluded that there was a need to develop validated methods
or analyzing these treatments.14
In humans, the results have been contradictory: accord-
ng to Andrade, there was no relationship between application
f the NASCIS II protocol and the patients’ evolution.15 How-
ver, among patients treated using MP  and surgery, there was
reater motor recovery than among patients who did not
ndergo this treatment.16
A meta-analysis on three studies on humans indicated that
reatment with MP  that was started not more  than 8 h after the
njury signiﬁcantly improved neurological functioning. One of
hese studies concluded that treatment with MP for 48 h pro-
ided additional beneﬁt, especially if the treatment was only
tarted beyond the ﬁrst 3 h.17
Although evidence of greater incidence of complications or
ortality through treatment with MP  is not always reported,17
he complications resulting from its use have generally been
ue to immunosuppressant effects (infections) and metabolic
1,18ffects (hyperglycemia). A statistically signiﬁcantly greater
umber of complications was observed among patients with
omplete ruptures.16 A signiﬁcantly greater risk of compli-
ations in general was seen among patients treated with;5 0(6):617–624 619
high doses of MP  (>5000 mg), along with signiﬁcantly greater
incidence of ulcers or gastric hemorrhage. No signiﬁcant dif-
ferences in intrahospital mortality were found between a
group that received high doses of MP  and a control group.19
Among patients hospitalized in intensive care, it was
seen that the risk of infection (especially respiratory infec-
tion) and hyperglycemia was signiﬁcantly greater among
patients treated with MP. There was no statistically signiﬁ-
cant difference in mortality and no differences in neurological
functioning were seen at the time of release from hospital,
between treated and untreated patients.18
Beneﬁts from treatment with MP  were thus only observed
in the NASCIS studies and in one or two other studies, and it
was seen that treatment with high doses of MP  increased the
risk of infection and consequently lengthened hospitalization
and dependence on mechanical ventilation. It was concluded
that until there was more  evidence, use of steroids for treating
spinal cord injuries should be suspended,2 considering that
the beneﬁts from the treatment might not compensate for the
adverse effects associated with this.20
In an article on ﬁrst-aid measures and treatment for spinal
and spinal cord injuries with fracturing, the authors reported
that they were currently only using MP  (using the NASCIS II
protocol) among patients with incomplete spinal cord injuries,
within the ﬁrst 8 h after the injury, given that they had not
observed any beneﬁts from this therapy among patients with
complete rupture.21
A review conducted in 2013 concluded that MP  could not
be considered to be a standard treatment for patients who
had suffered spinal or spinal cord injuries, but that it should
be kept as an option until new treatments of proven efﬁcacy
emerged.1
Tirilazad
Tirilazad is a 21-aminosteroid that acts in a manner similar
to corticoids, with inhibition of lipid peroxidation but without
immunosuppressant or metabolic effects.22
A review reported that tirilazad had beneﬁcial effects in
the NASCIS studies, but emphasized that there was a need to
develop new antioxidant therapies that were safer and more
effective.22
Drugs  that  interfere  with  edema,  ischemia  and
membrane  equilibrium
After injury, edema, ischemia and altered equilibrium of the
cell membranes of the spinal cord are observed.
GM1
GM1  is a ganglioside that intervenes in these processes,
through raising the neurotrophic factor levels and reducing
neuron destruction.23
A study on rats compared the effect of MP  with that of GM1.
MP resulted in signiﬁcant improvement of neurological func-
tion in relation to the control group. The group treated with
GM1  also showed better motor function, but the difference was
not statistically signiﬁcant. Combined treatment signiﬁcantly
p . 2 0 620  r e v b r a s o r t o 
improved motor function but in a less marked manner than
seen with MP  alone.23
In humans, no evidence of reduced mortality through treat-
ment with GM1  has been found.24
Apoptosis  inhibitors
Apoptosis is an important component of secondary spinal
cord lesions, which contributes toward loss of neurons and
oligodendrocytes.25 Several drugs inhibit apoptosis through
a variety of mechanisms, and these include inhibition
of caspases,25 inhibition of several intracellular signaling
routes26,27 and reduction of oxidative stress.28 A vast group
of drugs inhibits calpain, an endoprotease that promotes apo-
ptosis in several types of cells through proteolysis of proteins
in the cytoskeleton, membrane and myelin.29
Caspase  inhibitors
After experimental injury in rats, it was found that caspases
3, 8 and 9 became activated, especially in neurons and oligo-
dendrocytes. Intrathecal injection of Boc-d-fmk, a nonspeciﬁc
inhibitor of caspases, resulted in improvement of motor func-
tion observed on the 21st and 28th days after the experimental
spinal cord injury. Use of z-DEVD-fmk, a selective inhibitor
of caspase 3, led to functional improvement only on the
21st day after the injury.25 In another study, use of z-DEVD-
fmk  resulted in a lower degree of histological alterations
seen 24 h after the injury, with reduced apoptosis and sig-
niﬁcant improvement of motor function.30 In a comparison
between treatment with magnesium sulfate, an antagonist of
N-methyl-d-aspartate (NMDA) receptors, and use of z-LEDH-
fmk, along with combined treatment with both of these, a
histological but nonfunctional improvement was seen. No
statistically signiﬁcant differences were identiﬁed between
these two drugs.31 A group studied the effects of M50054, an
inhibitor of caspase-3, in ﬁsh with the capacity to regenerate
the central nervous system. A signiﬁcant reduction in apopto-
sis was observed over the medium to long term, among the
existing neurons, recently formed cells and recently differen-
tiated neurons, in association with faster functional recovery
among the treated ﬁsh.32
Calpain  inhibitors
The calpain inhibitor MDL28170 improved the survival of
Schwann cells, both in vitro, after exposure to hydrogen per-
oxide, and in vivo, after transplantation in the injured spinal
cord.33 Treatment with a single intravenous dose of this agent,
or with a daily dose administered intraperitoneally, resulted
in improvement of motor function, but not of the extent of
the lesion. Combination of these two forms of administration
improved both of the variables.29 Removal of calcium from the
medium or inhibition of calpain using MDL28170 avoided the
myelin retraction induced by exposure to glutamate.34Other calpain inhibitors have also been studied. SJA6017
signiﬁcantly reduced the degree of tissue damage and apo-
ptosis and signiﬁcantly improved motor function.35 In rats,
administration of calpain inhibitors led to formation of1 5;5 0(6):617–624
abnormal axon extremities that were swollen and did not
present microtubules. This suggests that activation of calpain
is necessary for effective regeneration.36
Drugs  that  interfere  with  other  routes
Spinal cord injury activates autophagia and apoptosis in
neurons and astrocytes. Inhibition of autophagia using
3-methyladenine has been found to result in worsened neu-
rological function, while its stimulation with rapamycin has
the opposite effect. These results suggest that stimulation of
autophagia has anti-apoptotic and neuroprotective effects.37
Treatment with aminoguanidine, an inhibitor of inducible
nitric oxide synthase (iNOS), has been found to lead to
improvement of motor function of the hind limbs of rats,
reduce mortality and reduce neuronal morphological alter-
ations. This treatment has also been shown to lead to
reduction of dephosphorylation of the pro-apoptotic phospho-
rylated Bcl-2-associated death promoter (p-BAD) protein and
reduction of iNOS expression, which results in lower release
of cytochrome c and mitochondria and reduces the degree of
apoptosis.38
Treatment with butein has been found to attenuate the
expression of protein p65 of the nuclear factor B (NF-B) and
to increase the phosphorylation of the  inhibitor of NF-B
(I-B). There was also a reduction in myeloperoxidase activ-
ity, which translated as lower neutrophil inﬁltration and less
expression of activated caspase-3. From this, it could be con-
cluded that there was a decrease in apoptosis.39
In another study, use of BMS-345541, an inhibitor of the
kinase pathway of I-B (IKK)/NF-B, avoided neutrophil inﬁl-
tration through reduction of the expression of the adhesion
molecule ICAM-1 and had anti-apoptotic effects through inhi-
bition of caspase 3 and modulation of the expression of Bcl-2
and Bax.40
A study on rats compared the effects of treatment with
ginkgolide B with the effects of methylprednisolone and
AG490, an inhibitor of the Janus kinase (JAK)/Stat pathway.
The animals treated with ginkgolide B or with MP  presented
signiﬁcantly better motor function than those of the control
group. The treatment with ginkgolide B and AG490 reduced
the activation of the JAK/Stat pathway and increased the Bcl-
2/Bax ratio, which resulted in an anti-apoptotic effect, with
lower expression of caspase-3 and reduction of the number of
TUNEL-positive cells. The treatment with ginkgolide B and MP
also resulted in greater neuron preservation.27
Inhibition of cyclin-dependent kinase-1 (CDK1) using CR8
or roscovitine resulted in reduction of apoptosis among
cultured cortical neurons, especially using CR8. In vivo, admin-
istration of CR8 resulted equally in greater neuron survival.26
Another possible therapeutic target is Rho-kinase, which
regulates a variety of events such as proliferation, differentia-
tion and cell death. Several studies have shown that inhibiting
this favors axon regeneration and neuron survival. Treatment
with fasudil, an inhibitor of this enzyme, reduced the his-
tological and functional alterations, activation of astrocytes,
activation of the NF-B pathway, expression of inﬂammatory
mediators, inﬁltration of neutrophils, expression of mitogen-
activated protein kinases (MAPK), activity of Rho-kinase and
expression of nitrotyrosine and poly-ADP-ribose (markers of
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did not have any effect on either of them. Treatment withr e v b r a s o r t o p . 2
xidative and inﬂammatory damage). Decreased expression
f Fas ligands and Bax and increased expression of Bcl-2 have
lso been observed. In the spinal cord of animals treated with
asudil, no apoptotic cells have been detected.28
In rats, treatment with 17-estradiol was found to reduce
poptosis of oligodendrocytes, loss of axons and activation
f caspases 3 and 9, homologue A of Ras (RhoA), c-Jun N-
erminal kinase (JNK) 3 and phosphorylated c-Jun (p-c-Jun)
evels, independently of the estrogen receptor. Administra-
ion of PEP-1-C3, a fusion protein that inhibits RhoA, was also
ound to reduce apoptosis of oligodendrocytes, JNK3 activ-
ty and p-c-Jun level, which conﬁrmed that this route has a
ole in inducing apoptosis.41 17-estradiol reduced the phos-
horylation of JNK and apoptosis of spinal neurons after
pinal cord injury in rats and reduced the phosphorylation
f JNK and the excitotoxicity induced by glutamate in vitro.42
n in vitro study tested the effects of estrogen and of an
gonist of estrogen receptor (ER)  (PPT) and an agonist of
R  (DPN) on motor neurons exposed to TNF-. All of these
ed to reduction of apoptosis, induction of phosphorylation
f extracellular-sign-regulated kinases (ERK) and increased
xpression of the respective receptors, with greater expression
f anti-apoptotic proteins. The agonists of estrogen recep-
ors inhibited both the intrinsic and the extrinsic pathway of
poptosis.43
Chicken embryos have the capacity to regenerate the spinal
ord until the 13th day of the embryonic period. Peptidy-
arginine deiminase 3 is a calcium-dependent protein that
as been implicated in loss of this capacity. Treatment with
l-amidine, a calcium chelant, has been found to reduce apo-
tosis and the extent of spinal cord injury in chicken embryos
ntil their 15th day of development.44
In a study on mice, apocynin, an inhibitor of reduced nic-
tinamide adenine dinucleotide phosphate (NADPH) oxidase,
ave rise to reduced inﬂammation, extent of spinal cord dam-
ge, inﬁltrating neutrophils, adhesion molecule expression,
F-B expression, nitrotyrosine and poly-ADP-ribose forma-
ion, pro-inﬂammatory cytokine levels, MAPK activation and
poptosis. An improvement in motor function was also seen.45
Pretreatment with U0126, an inhibitor of MAPK kinases
MEK), was found to lead to inhibition of phosphorylation of
RK1/2, reduction of apoptosis and greater neuron survival.
nhibition of MEK  induced phosphorylation of I-B, favored
inding of NF-B to AND and increased the expression of
poptosis-inhibiting cellular protein-2. A statistically signif-
cant improvement of motor function was observed in the
imbs affected.46
SP600125, an inhibitor of JNK, was found to produce
ncreased levels of p-BAD and the dimer BAD/14-3-3,
ecreased dimerization of BAD with Bcl-XL and Bcl-2, and
educed release of cytochrome c. There was also greater
reservation of the morphology of the mitochondria and
iminished apoptosis.47
Rolipram, an inhibitor of phosphodiesterase-4, was found
o induce growth of neurites and axon regeneration, unlike
P, but it did not reduce neuron death in vitro, or the lev-
ls of chondroitin sulfate proteoglycans, which was observed
ith MP. Combined treatment had an effect on these variables
hat was more  intense than monotherapy. Both of these drugs
igniﬁcantly diminished the volume of the lesion, and this;5 0(6):617–624 621
was more  markedly so in combination. Only the treatment
with both of these agents resulted in a signiﬁcant functional
improvement.48
Naloxone
Dynorphin A, an endogenous opioid that shows increased lev-
els after spinal cord injury, has neurotoxic effects and reduces
the arterial ﬂow. Naloxone, an antagonist of opioids, has been
used in some studies to counteract these effects.3 However, in
the NASCIS II study, naloxone did not show any neuroprotec-
tive effect.3
Antioxidant  drugs
Oxidative damage caused by reactive oxygen and peroxyni-
trite species is an important process in secondary lesions.
It leads to perturbation of ionic homeostasis, mitochondrial
dysfunction, potentiation of excitotoxicity and microvascular
lesions.22
Tempol is an antioxidant that reduces the levels of these
substances and diminishes inﬂammation through inhibiting
COX-2.49
In several studies, tempol has been shown to reduce
the oxidative damage mediated by peroxynitrite and the
mitochondrial respiratory dysfunction.50,51 Reductions in the
degradation of cytoskeleton proteins have also been observed
when treatment was administered within the ﬁrst hour after
the injury,50 along with reduction of COX-2 expression.49 The
area of the spinal cord that was irreversibly damaged was also
seen to be reduced through using tempol.49
In a study in which the effect of tempol was compared
with that of the uncoupling protein 2,4-dinitrophenol, the lat-
ter preserved the functioning of synaptic and nonsynaptic
mitochondria, whereas tempol only had an effect on nonsy-
naptic mitochondria.52
Another antioxidant, edaravone, was compared with MP
in a trial using rats. It was found that MP  had greater effect
regarding motor recovery than edaravone when the treatment
was administered within eight hours after the spinal cord
injury, while the opposite was seen when the treatment was
given more  than eight hours afterwards. There was greater
expression of Bcl-XL in the group treated with edaravone,
independent of the timing of the treatment. When the treat-
ment was administered within 8 h of the injury, there was
greater reduction of the expression of caspase-3 in the ani-
mals treated with MP, while beyond 8 h, only edaravone gave
rise to a signiﬁcant reduction.53
An in vivo and in vitro study evaluated the effect of MP  and
MnTBAP (an antioxidant) on the production of reactive oxy-
gen species. In vivo, both agents gave rise to diminution of
hydrogen peroxide production, but only MnTBAP signiﬁcantly
reduced the quantity of superoxide. In vitro, MnTBAP revealed
a capacity to capture both reactive oxygen species, but MPMnTBAP signiﬁcantly reduced the levels of markers of protein
nitration and lipid peroxidation, compared with the control.
Both of these drugs gave rise to signiﬁcant improvements in
p . 2 0 
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neurological functioning, and this was more  markedly so with
MnTBAP.54
Other  drugs
A study on mice evaluated the effect of cocaine and
amphetamine-regulated transcript (CART) peptides, alone or
in combination with MP. It was found that both of these
drugs improved motor function. The effect of MP was boosted
through concomitant administration of CART, even at a dose
that would be sub-effective as monotherapy. CART and MP
also reduced the numbers of astrocytes with positive marking
for GFAP and astrocytic hypertrophy. Histological abnormal-
ities were reduced in similar manners by CART, MP  and the
combined treatment.55
In a study on rats, the effects of MP  and magnesium were
evaluated. Administration of magnesium within eight hours
after the injury resulted in a signiﬁcant improvement in motor
function, in relation to the placebo group and to groups that
received magnesium after 12 or 24 hours. MP, magnesium and
their combination signiﬁcantly reduced the loss of white mat-
ter, but the combination was not shown to be better than the
separate treatment. None of the treatments had any signiﬁ-
cant effect on the myelin index.56
The Nogo-66 receptor is activated by three myelin
molecules and it inhibits the growth of neurites. A study in
which combined treatment consisting of MP and NEP1-40 (an
antagonist of Nogo-66) was used resulted in a greater increase
in survival of neurons and oligodendrocytes and signiﬁcantly
better motor recovery than among animals treated with only
one of these drugs.57
In a retrospective study on humans, it was found that there
was a more  signiﬁcant improvement in autonomy in relation
to activities of daily living through combined treatment con-
sisting of MP  and erythropoietin than with MP alone.58
In a study on rats that evaluated the effects of MP
and dexmedetomidine, both of these treatments signiﬁ-
cantly reduced the levels of TNF- and IL-6, along with the
inﬁltration of neutrophils.59 In another study, dexmedeto-
midine caused greater elevation of paraoxonase and IL-6,
along with greater reduction of hemorrhage, than MP. Both
of these agents reduced edema and necrosis to equal
degrees.60
Discussion
The evidence relating to the efﬁcacy of MP  is contradictory,
while evidence regarding its negative effects has been accu-
mulating. In the light of the present knowledge, use of MP  for
treating spinal and spinal cord injuries needs to be carefully
weighed up. Other anti-inﬂammatory agents have shown ben-
eﬁts for humans or animals, but further studies are required in
order to come to conclusions regarding its efﬁcacy and safety
in clinical practice.GM1  does not seem to have greater efﬁcacy than MP. Given
that the effects of this drug may only be shown later on, long-
term studies are needed in order to identify the beneﬁts of
GM1.231 5;5 0(6):617–624
Apoptosis is a complex process, with many  intervening
factors, and thus, drugs that inhibit it through various mecha-
nisms have been developed. The ones that have been studied
most seem to be caspase inhibitors and calpain inhibitors.
Many of these drugs have shown beneﬁts in in vitro studies
or in animal models.
Naloxone did not show any neuroprotective effect in the
NASCIS II study.
In the studies that have been conducted, tempol was
shown to inhibit the main consequences of oxidation at the
spinal cord level and is a promising form of therapy. Other
antioxidants seem to have effects that are superior to that of
MP, but further studies are needed in order to conﬁrm their
efﬁcacy.
Final  remarks
In order to address the enormous impact of spinal cord injuries
and the lack of effective therapeutic options for secondary
lesions, there is an urgent need to ﬁnd new treatments that
make it possible to improve the neurological status of patients
with spinal and spinal cord injuries. The beneﬁts of treat-
ment with methylprednisolone have been questioned, and
there are concerns regarding its safety. Other drugs that inter-
vene in inﬂammation or that have other mechanisms have
been studied. Some of these may be promising alternatives to
methylprednisolone. Additional studies are needed in order
to reach conclusions regarding the beneﬁt of these agents in
clinical practice.
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